| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514452000 | Plural ring oxygens in the hetero ring | 75 |
| 20080207743 | Biologically Active Taxane Analogs and Methods of Treatment - The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: | 08-28-2008 |
| 20080207744 | Biologically active taxane analogs and methods of treatment - The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: | 08-28-2008 |
| 20080293806 | Odor Reduction Compositions - An odor-reducing composition for counteracting malodour in which the composition includes an odor reducing material of the type phenyl ethyl methyl ether, Cyprisate, Camonal and paracresyl methyl ether and a method for counteracting malodour employing such a composition. | 11-27-2008 |
| 20090042973 | Inhibitors of aspartyl protease - The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity. | 02-12-2009 |
| 20090131511 | PALMARUMYCIN BASED INHIBITORS OF THIOREDOXIN AND METHODS OF USING SAME - Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer. | 05-21-2009 |
| 20090137660 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 05-28-2009 |
| 20090163576 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R | 06-25-2009 |
| 20090209634 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS - The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use of benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein to therapeutically or prophylactically treat, prevent, reverse, arrest or inhibit epileptogenesis and epilepsy. | 08-20-2009 |
| 20090247617 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES - The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders. | 10-01-2009 |
| 20090247618 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES - The present invention is directed to processes for the preparation of benzo-fused heteroaryl derivatives, useful for the treatment of epilepsy and related disorders. The present invention is further directed to processes for the preparation of intermediates in the synthesis of the benzo-fused heteroaryl derivatives. | 10-01-2009 |
| 20090286868 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS - A compound corresponding to general formula (I): | 11-19-2009 |
| 20090298928 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT - Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness. | 12-03-2009 |
| 20090318544 | CRYSTALLINE FORM OF (2S)-(-)-N-(6-CHLORO-2,3-DIHYDRO-BENZO[1,4]DIOXIN-2-YLMETHYL)-SULFAMIDE - The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form. | 12-24-2009 |
| 20100004324 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF - In one aspect, the invention relates to compounds and methods useful for activating heme sensor systems; for decreasing virulence of bacteria, for example, | 01-07-2010 |
| 20100029756 | NOVEL COMPOSITIONS CONTAINING ISOLATED TETRAMERIC TYPE A PROANTHOCYANADIN AND METHODS OF USE AND MANUFACTURE - The present invention relates to compositions containing an isolated novel tetrameric type A proanthocyanidin isomer having a formula of C | 02-04-2010 |
| 20100063138 | NOVEL SUBSTITUTED SULFAMIDE DERIVATIVES - The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse and as neuroprotective agents. The present invention is further directed to a process for the preparation of the novel substituted sulfamide derivatives. | 03-11-2010 |
| 20100087517 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES - The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 04-08-2010 |
| 20100105763 | PHARMACEUTICAL COMPOSITION, HEALTH FOOD COMPOSITION AND INOS INHIBITORS, CONTAINING THEOPEDERIN DERIVATIVES - The present invention relates to a pharmaceutical composition and a health food composition for the prevention and treatment of immune- and autoimmune diseases such as septic shock, hemorrhagic shock, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and multiple sclerosis, and metabolic diseases such as arteriosclerosis and type II diabetes, and an inducible nitric oxide synthase (iNOS) inhibitor composition containing theopederin derivatives as an active ingredient. The composition of the present invention can be effective in the prevention and treatment of immune diseases and metabolic diseases by inhibiting the excessive generation of NO by inhibiting the activity of iNOS. | 04-29-2010 |
| 20100179216 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF - Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. | 07-15-2010 |
| 20100184847 | COMPOSITIONS FOR SKIN PROTECTION AND IMPROVEMENT OF SKIN DISEASES CONTAINING THE DIBENZO-P-DIOXINE DERIVATIVES - The present invention relates to compositions for skin protection and improvement that contain dibenzo-p-dioxine derivatives as effective components. Since the compositions for skin protection and improvement that contain the dibenzo-p-dioxine derivative according to the present invention have excellent functions such as moisturizing and/or wrinkle prevention which are useful in prevention and improvement of various skin diseases, they can be extensively used as cosmetic ingredients or pharmaceutical agents for prevention and improvement of skin diseases. | 07-22-2010 |
| 20100204313 | Modulation of nerve pain activity by resiniferatoxin and uses thereof - The present invention is directed to the treatment of chronic pain that occurs in chronic disease such as chronic pancreatitis by the application, of the drug, resiniferatoxin, to a visceral organ, such as the stomach, which then reduces the pain present in a second visceral organ, such as the pancreas. The reduction of said pain associated with the chronic disease occurs through the drug-induced desensitization of primary pain-sensing neurons that are shared between the two visceral organs. Additionally, application of the drug resiniferatoxin into the first organ, reduces the inflammation that occurs in the second diseased organ. This modulation of shared nerve activity by application of resiniferatoxin, may also be directed to modulate the pain and inflammation in any two visceral organs that share a common spinal or vagal nerve. Finally, application of the drug resiniferatoxin to either the stomach or the jejunum may be used to treat disease and disorders that involve gastroparesis. The resiniferatoxin improves gastric emptying and reduces nausea, thus may be effective therapy for these conditions. | 08-12-2010 |
| 20100324130 | DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT - Peripheral Benzodiazepine Receptor (PBR) is an attractive target for tumor imaging and treatment due to its up-regulation in numerous cancer cell types. DAA1 106 is a selective PBR ligand with high binding affinity. Aspects of the present invention are series of functionalized DAA1 106 analogs, which can be conjugated to a variety of signaling and treatment moieties, and are widely applicable in PBR targeted molecular imaging and drug delivery. | 12-23-2010 |
| 20110009480 | Biologically active taxane analogs and methods of treatment - The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: | 01-13-2011 |
| 20110021614 | USE OF SILYMARIN AND SILYBIN IN THE TREATMENT OF NEURAL INJURY - The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin. | 01-27-2011 |
| 20110028539 | Biologically active taxane analogs and methods of treatment - The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: | 02-03-2011 |
| 20110077292 | FORSKOLIN CARBONATES AND USES THEREOF - The present invention provides methods for reducing body weight. In particular, the present invention provides methods for reducing body weight by administering a composition comprising a forskolin 1α,9α-carbonate compound of the formula: | 03-31-2011 |
| 20110124718 | Reduction Of Acetaminophen Toxicity By Dietary Milk Thistle Extract - The present invention is directed to the reduction of acetaminophen toxicity by dietary milk thistle extract. Milk thistle has been reported to have protective effects on the liver and to greatly improve its function. It is typically used to treat liver cirrhosis, chronic hepatitis (liver inflammation), and toxin-induced liver damage. The present invention, for the first time, combines milk thistle and acetaminophen in a unique and novel way to provide single dosages containing both ingredients, whether dispensed in a liquid suspension, chewable tablets, coated caplets, gelcaps, geltabs, and suppositories. | 05-26-2011 |
| 20110207805 | COMPOSITION OF FLAVANOLIGNAN AND AMINO ACID WITH IMPROVED WATER SOLUBILITY - The invention relates to a composition containing flavanolignans, e.g., isolated from | 08-25-2011 |
| 20110294875 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 12-01-2011 |
| 20120029064 | FORMULATION OF SILIBININ WITH HIGH EFFICACY AND PROLONGED ACTION AND THE PREPARATION METHOD THEREOF - A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silibinin solid dispersion:silibinin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silibinin-loaded silica nanoparticles is 51.29˜51.77%; the said silibinin solid dispersion contains povidone K30, soybean lecithin, acrylic resin IV, wherein the mass ratio between silibinin and other medical accessories is silibinin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silibinin disclosed in this invention is 14.8 times longer while the mean residence time (MRT) of which is 4.52 times longer; when tested in vivo in Beagle dogs, this new formulation of silibinin presents a smoother concentration-time curve and reaches the continuous release for 72 hours. This invention discloses its preparation method. | 02-02-2012 |
| 20120041058 | COMPOSITION OF TRADITIONAL CHINESE MEDICINE FOR REDUCING BLOOD FAT AND PREPARATION METHOD THEREOF - Composition of traditional Chinese medicine for reducing blood lipid with components of the crude drug of artemisinins and the crude drug of ursolic acid, wherein the ratio of the crude drug of artesunate and the crude drug of ursolic acid is 1:25-25:1 by weight. The preparation method of such composition includes the following steps: the crude drug of artesunate and the crude drug of ursolic acid are mixed at the weight ratio mentioned above, comminuted, then screened through 120 mesh sieve to obtain the composition; or the crude drug of artesunate and the crude drug of ursolic acid are weighed at the weight ratio mentioned above, comminuted, screened through 120 mesh sieve separately, then mixed and screened for three times to obtain the composition. The composition of the present invention can be formulated into formulations for injection, oral administration with pharmaceutically acceptable carriers, and can be used for preparing medicaments for reducing blood lipid. | 02-16-2012 |
| 20120088823 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT - Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness. | 04-12-2012 |
| 20120122965 | COMPOSITIONS FOR SKIN PROTECTION AND IMPROVEMENT OF SKIN DISEASES CONTAINING THE DIBENZO-P-DIOXINE DERIVATIVES - The present invention relates to compositions for skin protection and improvement that contain dibenzo-p-dioxine derivatives as effective components. | 05-17-2012 |
| 20120142766 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES - The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 06-07-2012 |
| 20120157520 | DIOXANES DERIVED FROM REGROUPING CARBOHYDRATES AND C-GLYCOSIDES, PROCESS FOR OBTAINING SAME AND USES THEREOF - The present invention relates to compounds with a dioxane nucleus derived from carbohydrates and C-glucosides, process for obtaining same, to the use of such compounds as cytotoxic and antiproliferative agents and to the use thereof for producing a cancer treatment drug. | 06-21-2012 |
| 20120178799 | ENERGY BEVERAGE WITH CREATINE AND CAFFEINE COMBINATION - The present invention is an energy drink that included both creatine and caffeine, which provides superior energy, concentration and performance over other energy beverages/liquids. The invention can include other vitamins and beneficial additives, but is intended to be unflavored and unsweetened. | 07-12-2012 |
| 20120178800 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition having two components. The first component is glutaraldehyde. The second component is 2,6-dimethyl-1,3-dioxan-4-yl acetate. | 07-12-2012 |
| 20120196926 | BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - Provided are benzopyran compounds of formula I, for example, pomiferin-3′,4′-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. | 08-02-2012 |
| 20120316230 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds of formula (I), where R | 12-13-2012 |
| 20130085175 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES - The present invention is directed to an improved process for the preparation of sulfamide derivatives. | 04-04-2013 |
| 20130085176 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES - The present invention is directed to a process for the preparation of sulfamide derivatives. | 04-04-2013 |
| 20130178516 | EXTRACTS OF CHENOPODIUM AMBROSIOIDES L., THE COMPOSITIONS COMPRISING SAID EXTRACTS, THE PREPARING PROCESS AND APPLICATION THEREOF - The present invention relates to plant extracts, specifically, the extracts of Chinese medicine | 07-11-2013 |
| 20130210905 | Selective Ablation of Pain-Sensing Neurons by Administration of a Vanilloid Receptor Agonist - The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons. | 08-15-2013 |
| 20130217760 | METHOD FOR ENHANCING THERAPEUTIC EFFECT OF ANTICANCER THERAPIES - Disclosed is a method for enhancing therapeutic effect of anticancer therapies for an animal, comprising administering one or more dibenzo-p-dioxin derivative in an effective amount to the animal in anticancer therapies. The method augments therapeutic effects of an anticancer therapies, with the suppression of side effects of the anticancer therapies. | 08-22-2013 |
| 20130253044 | TAXANE ANALOGS FOR THE TREATMENT OF BRAIN CANCER - Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer. | 09-26-2013 |
| 20130253045 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses - The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 09-26-2013 |
| 20130303601 | Acid-Labile Lipophilic Prodrugs of Cancer Chemotherapeutic Agents - The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof. | 11-14-2013 |
| 20130338217 | ANTIBIOTIC COMPOSITION INCLUDING PHLOROTANNIN COMPOUND DERIVED FROM EISENIA BICYCLIS AS EFFECTIVE COMPONENT - There is provided an antibiotic composition including | 12-19-2013 |
| 20130338218 | HIV-1 INHIBITING PHARMACEUTICAL COMPOSITION CONTAINING AN ECKLONIA CAVA-DERIVED PHLOROGLUCINOL POLYMER COMPOUND - The present invention relates to a HIV-1 inhibiting pharmaceutical composition containing, as an active ingredient, 6,6′-bieckol which is a phloroglucinol polymer compound separated from Ecklonia cava. The Ecklonia cava-derived 6,6′-bieckol according to the present invention inhibits HIV-1 induced cell fusion, the cell lysis effect, and the cytopathogenic effect including virus p24 antibody production, exhibits RT enzyme inhibition activity and HIV-1 infection inhibition activity, and shows no cytotoxicity at the concentration that almost perfectly inhibits HIC-1 replication. | 12-19-2013 |
| 20140018414 | METHODS OF INDUCING ANESTHESIA - The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. | 01-16-2014 |
| 20140080902 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS - The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases. | 03-20-2014 |
| 20140171496 | COMPOSITION AND METHOD FOR PROMOTING HAIR GROWTH - The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof. | 06-19-2014 |
| 20140179773 | METHOD FOR THE TREATMENT OF HEART RELATED DISORDERS IN NAFLD PATIENTS - The present invention concerns the field of heart related disorders in NAFLD patients, and in particular relates to a method of treatment suitable for improving the conditions of heart injury and myocardial related damage in such patients. | 06-26-2014 |
| 20140194497 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT - Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness. | 07-10-2014 |
| 20140243404 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY - This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed. A representative halonium compound of the disclosure is: | 08-28-2014 |
| 20140249213 | Acid-Labile Lipophilic Prodrugs of Cancer Chemotherapeutic Agents - The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof. | 09-04-2014 |
| 20140303241 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF - The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma. | 10-09-2014 |
| 20150011617 | COMBINED USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS AND SILYMARIN IN THE TREATMENT OF RENAL DISEASES - A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases. The mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or of a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol and said Silymarin, derivatives thereof or conjugates or complexes thereof are formulated for a separate, sequential, concomitant administration or in admixture, also in a co-micronized or co-ultra-micronized form. | 01-08-2015 |
| 20150025129 | COMPOUNDS, COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE - Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof. | 01-22-2015 |
| 20150025130 | STEROL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF - The present disclosure discloses a sterol derivative, a preparation method therefor and a use thereof. The sterol derivative includes a sterol compound with Structural Formula (I) or a pharmaceutically acceptable salt thereof, or an extract containing the sterol compound, or a composition containing the sterol compound, wherein Structural Formula (I) is as follows: | 01-22-2015 |
| 20150045420 | SKIN CARE COMPOSITIONS HAVING CYCLIC DIESTERS AND METHODS THEREOF - The present invention generally relates to topical skin care compositions having at least one cyclic diester. More specifically, the present invention relates to novel topical skin care compositions having at least one cyclic diester of an alpha hydroxy acid, and at least one polar non-aqueous solvent. | 02-12-2015 |
| 20150045421 | SKIN CARE COMPOSITIONS HAVING CYCLIC DIESTERS AND METHODS THEREOF - The present invention generally relates to topical skin care compositions having at least one cyclic diester. More specifically, the present invention relates to novel topical skin care compositions having at least one cyclic diester of an alpha hydroxy acid, and at least one polar non-aqueous solvent. | 02-12-2015 |
| 20150051270 | Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease - A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: | 02-19-2015 |
| 20150051271 | SELECTIVE ABLATION OF PAIN-SENSING NEURONS BY ADMINISTRATION OF A VANILLOID RECEPTOR AGONIST - The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons. | 02-19-2015 |
| 20150080460 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin - There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column. | 03-19-2015 |
| 20150105453 | Methods for making and using novel semi-synthetic small molecules for the treatment parasitic disease - Small molecule therapeutics for the treatment of parasitic diseases, in particular, semi-synthetic derivatives of the fugally-derived natural product merulin A for the treatment of African Sleeping Sickness. | 04-16-2015 |
| 20150133536 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof - Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G′ or Formula M′: | 05-14-2015 |
| 20150291547 | SMALL MOLECULES FOR EXTENDING THE WELL BEING OF CELLS AND METHODS OF USE THEREOF - The present invention relates to use of a series of compounds and compositions comprising the same for enhancing telomerase expression and/or activating telomerase activity in a cell or tissue of a subject and for treatment of diseases, disorders and/or conditions capable of being affected by enhanced telomerase expression and/or telomerase activation. | 10-15-2015 |
| 20150299157 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS - The present application discloses a compound which is | 10-22-2015 |
| 20150344455 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION - The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein. | 12-03-2015 |
| 20160009728 | ANTICANCER COMPOUNDS | 01-14-2016 |
| 20160158193 | ADJUVANTS IN ANTI-CANCER CHEMOTHERAPY - The present invention provides a 1,2,4-trioxane or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof for use as an adjuvant for a tyrosine kinase inhibitor to enhance the activity of said tyrosine kinase inhibitor in a method for the treatment of a patient suffering from cancer, a pharmaceutical composition comprising a tyrosine kinase inhibitor as an active ingredient and said 1,2,4-trioxane adjuvant or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof in an amount sufficient to enhance the activity of the tyrosine kinase inhibitor, preferably for use in a method for the treatment of cancer. | 06-09-2016 |
| 20160175279 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS | 06-23-2016 |
| 20190142784 | 9,10-Alpha,Alpha-OH-Taxane Analogs and Methods for Production Thereof | 05-16-2019 |
| 20220133687 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS - A method for treating or preventing a neurodegenerative disease in a subject, the method comprising administering an HGF activating compound in a therapeutically effective amount to treat or prevent the neurodegenerative disease by activating HGF in the subject. The neurodegenerative disease may be, for example, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, dementia, or mild cognitive impairment. The methods may also be more generally directed to improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens. | 05-05-2022 |
